Title:The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells
VOLUME: 20 ISSUE: 12
Author(s):Zhenyu Ye, Yecheng Li, Jiaming Xie, Zhenyu Feng, Xiaodong Yang, Yong Wu, Kui Zhao, Yuwei Pu, Xiangrong Xu, Zhaobi Zhu, Wei Li, Jun Pan, Wei Chen* and Chungen Xing*
Affiliation:Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004
Keywords:PDAC, afatinib, BxPC3-AR, BXPC3-PA, autophagy, poor prognosis.
Abstract:Background: Pancreatic Ductal Adenocarcinoma (PDAC) is the most common form of pancreatic
cancer and leading causes of pancreatic cancer death because of most PDAC patients with advanced unresectable
disease at that time, which is remarkably resistant to all forms of chemotherapy and radiotherapy.
Objective: PDAC increases the social and patient's family burden. However, the PDAC pathogenesis is not
identified. We are trying to uncover the underlying mechanism in the future.
Methods: In our research, the drug-resistant cell line was successfully induced in the vitro by progressive concentrations
of Afatinib, which we named it as BxPC3-AR.
Results: It has been observed that the effect of autophagy was on the resistance of BxPC3-AR to Afatinib.
Conclusion: It has been confirmed that autophagy plays a certain role in BxPC3-AR resistance to Afatinib. Our
findings provide a new perspective on the role of autophagy in pancreatic ductal adenocarcinoma.